News coverage about TRACON Pharmaceuticals (NASDAQ:TCON) has trended somewhat positive on Tuesday, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. TRACON Pharmaceuticals earned a daily sentiment score of 0.20 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 46.2496013358534 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news articles that may have effected Accern Sentiment’s scoring:
- TRACON Pharmaceuticals Announces Appointment of Brian Daniels, MD, to Scientific Advisory Board – GlobeNewswire (press release) (globenewswire.com)
- TRACON Pharmaceuticals Announces Appointment of Brian Daniels, M.D., to Scientific Advisory Board (finance.yahoo.com)
- TRACON Doses First Patient in Phase 1b Study of TRC105 with Opdivo® in Patients with Lung Cancer – Markets Insider (markets.businessinsider.com)
- Zacks: Analysts Anticipate TRACON Pharmaceuticals, Inc. (TCON) Will Post Quarterly Sales of $710,000.00 (americanbankingnews.com)
Separately, Zacks Investment Research downgraded shares of TRACON Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th.
TRACON Pharmaceuticals (NASDAQ:TCON) traded up $0.15 during mid-day trading on Tuesday, hitting $3.05. 169,300 shares of the stock were exchanged, compared to its average volume of 102,262. TRACON Pharmaceuticals has a twelve month low of $2.00 and a twelve month high of $6.25. The company has a debt-to-equity ratio of 0.24, a current ratio of 3.80 and a quick ratio of 3.80.
TRACON Pharmaceuticals (NASDAQ:TCON) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.32. TRACON Pharmaceuticals had a negative net margin of 201.21% and a negative return on equity of 83.43%. The business had revenue of $7.50 million during the quarter, compared to the consensus estimate of $7.60 million. analysts anticipate that TRACON Pharmaceuticals will post -1.21 EPS for the current year.
TRACON Pharmaceuticals Company Profile
TRACON Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring).
Receive News & Ratings for TRACON Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.